Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs, which are used to treat viral infections, have become increasingly important in the healthcare sector in recent years. Thailand, a country in Southeast Asia, has experienced significant growth in the antiviral drugs market.
Customer preferences: Customers in Thailand are increasingly concerned about their health and are willing to invest in antiviral drugs to prevent and treat viral infections. The COVID-19 pandemic has also increased awareness about the importance of antiviral drugs, leading to a surge in demand.
Trends in the market: One of the key trends in the antiviral drugs market in Thailand is the increasing focus on research and development. Local pharmaceutical companies are investing in the development of new antiviral drugs to meet the growing demand. Another trend is the rise in demand for combination therapies, which involve the use of multiple antiviral drugs to treat viral infections. Additionally, there has been a shift towards generic antiviral drugs, which are more affordable than branded drugs.
Local special circumstances: Thailand has a large population of people living with HIV/AIDS, which has led to a significant demand for antiviral drugs. The government has implemented several programs to provide free antiviral drugs to people living with HIV/AIDS, which has further boosted the market. Additionally, Thailand is a popular destination for medical tourism, with many people traveling to the country to receive affordable medical treatment, including antiviral drugs.
Underlying macroeconomic factors: Thailand has a growing economy, which has led to an increase in healthcare spending. The government has also implemented several policies to promote the development of the pharmaceutical industry, including tax incentives and funding for research and development. Furthermore, Thailand has a strong manufacturing sector, which has allowed local pharmaceutical companies to produce antiviral drugs at a lower cost, making them more affordable for customers.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
